Jason J Schwartz1,2, Lyska Emerson3, Elaine Hillas4, Ann Phan4, Heather Thiesset5, Matthew Firpo4, Jeffrey Sorensen4, Thomas Kennedy6, Mary Rinella7. 1. Division of Transplantation, Department of Surgery, University of Texas, Southwestern, 5323 Harry Hines Blvd, Dallas, TX, USA. jason.schwartz@utsouthwestern.edu. 2. Department of General Surgery, University of Utah, Salt Lake City, UT, USA. jason.schwartz@utsouthwestern.edu. 3. Department of Pathology, University of Utah, Salt Lake City, UT, USA. lyska.emerson@hsc.utah.edu. 4. Department of General Surgery, University of Utah, Salt Lake City, UT, USA. 5. Department of General Surgery, University of Utah, Salt Lake City, UT, USA. heather.thiesset@hsc.utah.edu. 6. Georgia Health Sciences University, Section of Pulmonology, Augusta, GA, USA. TKennedy@georgiahealth.edu. 7. Department of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. m-rinella@northwestern.edu.
Abstract
PURPOSE: The process whereby liver inflammation develops in non-alcoholic steatohepatitis (NASH) is not fully understood. While modification of the inflammatory milieu is an attractive target to prevent the development of hepatocellular injury, most antiinflammatory agents have proven ineffective in this setting. Tetraethylthiuram disulfide (TDSF) is able to induce S-glutathionylation of NF-κB along with critical signaling proteins involved with inflammation, especially when complexed with a heavy metal. For this reason, we hypothesized that administration of TDSF would function to ameliorate necroinflammatory activity in a mouse model of NASH. METHODS: Mice were divided into five groups and received control chow versus a methionine-choline-deficient diet. After 6 weeks of TDSF versus sham gavage, animals were necropsied. Using conventional H&E staining, livers were examined using the Brunt scoring system by a hepatopathologist blinded to treatment groups. Validated mouse primer sets were used for quantitative real-time PCR to evaluate changes in mRNA expression. RESULTS: Livers treated with TDSF demonstrated a qualitative reduction in lobular inflammation, lipogranuloma formation, and Kupffer cell accumulation, but not steatosis. Significant reductions in inflammatory transcripts for α-1-collagen, TGF-β, Mmp2, MCP-1, and TNF-1α were also observed. CONCLUSIONS: Animals treated with TDSF exhibit a reduction in lobular inflammation that is independent of lipid accumulation when administered MCD diet. Similar reductions are seen in several inflammatory transcripts associated with NASH. Additional work in this area may reveal a therapeutic role for TDSF or similar agents in curtailing inflammatory signaling within the liver.
PURPOSE: The process whereby liver inflammation develops in non-alcoholic steatohepatitis (NASH) is not fully understood. While modification of the inflammatory milieu is an attractive target to prevent the development of hepatocellular injury, most antiinflammatory agents have proven ineffective in this setting. Tetraethylthiuram disulfide (TDSF) is able to induce S-glutathionylation of NF-κB along with critical signaling proteins involved with inflammation, especially when complexed with a heavy metal. For this reason, we hypothesized that administration of TDSF would function to ameliorate necroinflammatory activity in a mouse model of NASH. METHODS:Mice were divided into five groups and received control chow versus a methionine-choline-deficient diet. After 6 weeks of TDSF versus sham gavage, animals were necropsied. Using conventional H&E staining, livers were examined using the Brunt scoring system by a hepatopathologist blinded to treatment groups. Validated mouse primer sets were used for quantitative real-time PCR to evaluate changes in mRNA expression. RESULTS: Livers treated with TDSF demonstrated a qualitative reduction in lobular inflammation, lipogranuloma formation, and Kupffer cell accumulation, but not steatosis. Significant reductions in inflammatory transcripts for α-1-collagen, TGF-β, Mmp2, MCP-1, and TNF-1α were also observed. CONCLUSIONS: Animals treated with TDSF exhibit a reduction in lobular inflammation that is independent of lipid accumulation when administered MCD diet. Similar reductions are seen in several inflammatory transcripts associated with NASH. Additional work in this area may reveal a therapeutic role for TDSF or similar agents in curtailing inflammatory signaling within the liver.
Authors: John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust Journal: J Hepatol Date: 2006-03-20 Impact factor: 25.083
Authors: Yanqiao Zhang; Lawrence W Castellani; Christopher J Sinal; Frank J Gonzalez; Peter A Edwards Journal: Genes Dev Date: 2004-01-16 Impact factor: 11.361
Authors: A Drori; D Rotnemer-Golinkin; S Avni; A Drori; O Danay; D Levanon; J Tam; L Zolotarev; Y Ilan Journal: BMC Gastroenterol Date: 2017-11-28 Impact factor: 3.067